Skip to main content

Market Overview

What's Going On With CELC Stock And PRVB Stock Today?

What's Going On With CELC Stock And PRVB Stock Today?

Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib.

Celcuity is a cellular analysis company that is discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. 

The company's proprietary CELx diagnostic platform uses the patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it.

Provention Bio Inc (NASDAQ: PRVB) shares are trading lower after the company offered a regulatory update on its Biologics License Application for teplizumab for the delay or prevention of clinical type 1 diabetes in at-risk individuals.

RBC Capital analyst Gregory Renza also downgrades Provention Bio from Outperform to Sector Perform and lowers the price target from $25 to $10.

Provention Bio Inc is a clinical-stage biopharmaceutical company. It is engaged in sourcing, developing, and commercializing novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease, including oncological, autoimmune, and inflammatory diseases.


Related Articles (PFE + CELC)

View Comments and Join the Discussion!

Posted-In: News Downgrades Price Target Small Cap Analyst Ratings

Latest Ratings

CMRXHC Wainwright & Co.Maintains18.0
PZZAStephens & Co.Maintains115.0
STAACanaccord GenuityMaintains150.0
DGIICanaccord GenuityMaintains25.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at